ArticleLa Radiologia medica2025
First clinical application of Comprehensive Motion Management with 1.5T MR-linac on prostate cancer patients treated with radiotherapy: technical aspects and suggested workflow recommendations.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MR-guided stereotactic radiosurgery of an intracardiac tumoral thrombus using comprehensive motion management.Clinical and translational radiation oncology · 2026Article
- First experimental demonstration of magnetic resonance-guided multileaf collimator tracking for (ultra-)hypofractionated prostate radiotherapy.Physics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMR-guided radiotherapy (MRgRT) on the MR-linac (MRL) with daily online plan adaptation enables better control of inter-fraction variability. Recently, Comprehensive Motion Management (CMM) was introduced for the 1.5T MRL. CMM halts dose delivery when the target moves outside its defined position and allows for target drift corrections, compensating for intra-fraction variability. This study aims to report the first clinical experience with prostate MRgRT using CMM, focusing on intra-fraction motion management and treatment delivery time. MATERIAL AND
methodsSixty patients with low- to intermediate-risk prostate cancer were treated with the 1.5T MRL using CMM. PTV margins were 5 mm in all directions, with a 3-mm margin posteriorly. Fifty patients received ultra-hypofractionated radiotherapy (SBRT), and 10 received hypofractionated radiotherapy (hypoRT). The CMM threshold was set to 100% of the GTV volume.
resultsA total of 450 treatment fractions were administered. The median beam-on time was 10.3 min, with a median duty cycle of 98.9% (95% CI 98.6-99.2%). Beam hold occurred in 158 fractions (35%), with an average of 24.5 instances per fraction (95% CI 16-32). Thirty-two baseline shift replans were performed. Both acute and late toxicities were low, with no Grade 3 or higher toxicities.
conclusionsCMM has been successfully implemented in MRgRT. In-treatment corrections and baseline shift replanning did not significantly impact treatment time, enhancing treatment quality without compromising patient compliance or treatment feasibility. The low incidence of beam-hold events suggests that CMM could potentially allow for a safe reduction in PTV margins.
Indexed as
Identifiers
40257694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.